JOP20220024A1 - مركبات مساعدة لـ gipr - Google Patents
مركبات مساعدة لـ giprInfo
- Publication number
- JOP20220024A1 JOP20220024A1 JOP/2022/0024A JOP20220024A JOP20220024A1 JO P20220024 A1 JOP20220024 A1 JO P20220024A1 JO P20220024 A JOP20220024 A JO P20220024A JO P20220024 A1 JOP20220024 A1 JO P20220024A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- gipr
- agonist compounds
- useful
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات لها نشاط عند مستقبل بشري لبولي ببتيد مفرز للإنسولين يتوقف على الجلوكوز(GIP). ويتعلق الاختراع الحالي أيضًا بمركبات تتضمن مدة تأثير ممتدة عند مستقبل GIP. قد تكون هذه المركبات مفيدة في علاج مرض السكري، بما في ذلك داء السكري من النوع 2 (“T2DM”). علاوة على ذلك، قد تكون المركبات مفيدة في علاج السمنة.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881685P | 2019-08-01 | 2019-08-01 | |
| PCT/US2020/043988 WO2021021877A1 (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220024A1 true JOP20220024A1 (ar) | 2023-01-30 |
Family
ID=72145469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0024A JOP20220024A1 (ar) | 2019-08-01 | 2020-07-29 | مركبات مساعدة لـ gipr |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11254721B2 (ar) |
| EP (1) | EP4007593A1 (ar) |
| JP (2) | JP7230272B2 (ar) |
| KR (1) | KR20220028007A (ar) |
| CN (1) | CN114206915A (ar) |
| AR (1) | AR119471A1 (ar) |
| AU (1) | AU2020322784A1 (ar) |
| BR (1) | BR112022000027A2 (ar) |
| CA (1) | CA3145608A1 (ar) |
| CL (1) | CL2022000140A1 (ar) |
| CO (1) | CO2022000759A2 (ar) |
| CR (1) | CR20220020A (ar) |
| DO (1) | DOP2022000025A (ar) |
| EC (1) | ECSP22008098A (ar) |
| IL (1) | IL289463A (ar) |
| JO (1) | JOP20220024A1 (ar) |
| MX (1) | MX2022001137A (ar) |
| PE (1) | PE20220938A1 (ar) |
| TW (1) | TWI764209B (ar) |
| WO (1) | WO2021021877A1 (ar) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| TW202317174A (zh) * | 2020-12-18 | 2023-05-01 | 美商美國禮來大藥廠 | 雙重澱粉素及降鈣素受體促效劑及其用途 |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
| WO2024080650A1 (ko) * | 2022-10-12 | 2024-04-18 | 서울대학교병원 | Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법 |
| CN116410298B (zh) * | 2023-06-06 | 2023-08-11 | 诺博泰科(成都)生物科技有限公司 | 一种三激动多肽化合物及其盐、药用组合物、药剂和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
| BR112017008659A2 (pt) * | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| AR110301A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| JP2022503793A (ja) | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
-
2020
- 2020-07-23 AR ARP200102070A patent/AR119471A1/es unknown
- 2020-07-23 TW TW109124879A patent/TWI764209B/zh active
- 2020-07-29 CN CN202080056086.3A patent/CN114206915A/zh active Pending
- 2020-07-29 AU AU2020322784A patent/AU2020322784A1/en active Pending
- 2020-07-29 CR CR20220020A patent/CR20220020A/es unknown
- 2020-07-29 JO JOP/2022/0024A patent/JOP20220024A1/ar unknown
- 2020-07-29 WO PCT/US2020/043988 patent/WO2021021877A1/en active Application Filing
- 2020-07-29 PE PE2022000145A patent/PE20220938A1/es unknown
- 2020-07-29 EP EP20758004.4A patent/EP4007593A1/en active Pending
- 2020-07-29 JP JP2022506052A patent/JP7230272B2/ja active Active
- 2020-07-29 KR KR1020227002903A patent/KR20220028007A/ko not_active Application Discontinuation
- 2020-07-29 MX MX2022001137A patent/MX2022001137A/es unknown
- 2020-07-29 BR BR112022000027A patent/BR112022000027A2/pt unknown
- 2020-07-29 CA CA3145608A patent/CA3145608A1/en active Pending
- 2020-07-29 US US16/941,990 patent/US11254721B2/en active Active
-
2021
- 2021-12-28 IL IL289463A patent/IL289463A/en unknown
-
2022
- 2022-01-11 US US17/573,317 patent/US11897926B2/en active Active
- 2022-01-20 CL CL2022000140A patent/CL2022000140A1/es unknown
- 2022-01-27 CO CONC2022/0000759A patent/CO2022000759A2/es unknown
- 2022-01-31 DO DO2022000025A patent/DOP2022000025A/es unknown
- 2022-02-01 EC ECSENADI20228098A patent/ECSP22008098A/es unknown
-
2023
- 2023-02-15 JP JP2023021452A patent/JP2023062068A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20220938A1 (es) | 2022-05-31 |
| KR20220028007A (ko) | 2022-03-08 |
| CA3145608A1 (en) | 2021-02-04 |
| AR119471A1 (es) | 2021-12-22 |
| JP7230272B2 (ja) | 2023-02-28 |
| CL2022000140A1 (es) | 2022-09-30 |
| EP4007593A1 (en) | 2022-06-08 |
| TW202126680A (zh) | 2021-07-16 |
| ECSP22008098A (es) | 2022-03-31 |
| IL289463A (en) | 2022-02-01 |
| BR112022000027A2 (pt) | 2022-05-24 |
| JP2022544061A (ja) | 2022-10-17 |
| CO2022000759A2 (es) | 2022-02-07 |
| MX2022001137A (es) | 2022-02-16 |
| CR20220020A (es) | 2022-02-14 |
| DOP2022000025A (es) | 2022-03-15 |
| AU2020322784A1 (en) | 2022-02-03 |
| WO2021021877A1 (en) | 2021-02-04 |
| JP2023062068A (ja) | 2023-05-02 |
| US20220127315A1 (en) | 2022-04-28 |
| US11897926B2 (en) | 2024-02-13 |
| US20210032299A1 (en) | 2021-02-04 |
| CN114206915A (zh) | 2022-03-18 |
| US11254721B2 (en) | 2022-02-22 |
| TWI764209B (zh) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220020A (es) | Compuestos agonistas de gipr | |
| PH12021550154A1 (en) | Gip/glp1 co-agonist compounds. | |
| MD3242887T2 (ro) | Compuși co-agonişti ai GIP și GLP-1 | |
| PH12020551742A1 (en) | Gip derivatives and uses thereof | |
| PH12020551025A1 (en) | Incretin analogs and uses thereof | |
| EA201290027A1 (ru) | Ацилированные аналоги глюкагона | |
| JOP20200136A1 (ar) | نظائر إنكريتين واستخداماتها | |
| EA201291234A1 (ru) | Аналоги глюкагона | |
| EA201190054A1 (ru) | Аналоги глюкагона | |
| EA201190047A1 (ru) | Аналоги глюкагона | |
| EA201190049A1 (ru) | Аналоги глюкагона | |
| MX2011006315A (es) | Analogos de glucagon. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| MX2022007666A (es) | Analogos de incretina y sus usos. | |
| EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 |